Benznidazole in Chagas disease study: do the data justify progression to phase 3?
Lancet Infect Dis
.
2021 Aug;21(8):1066-1067.
doi: 10.1016/S1473-3099(21)00320-0.
Author
Enrica Alteri
1
Affiliation
1
Formerly of Division Human Medicines R&D Support, European Medicines Agency, Amsterdam, Netherlands. Electronic address: enrica.alteri@gmail.com.
PMID:
34331878
DOI:
10.1016/S1473-3099(21)00320-0
No abstract available
Publication types
Letter
Comment
MeSH terms
Chagas Disease* / drug therapy
Chagas Disease* / epidemiology
Humans
Nitroimidazoles* / therapeutic use
Substances
Nitroimidazoles
benzonidazole